A detailed history of Group One Trading, L.P. transactions in Cellectis S.A. stock. As of the latest transaction made, Group One Trading, L.P. holds 1,523 shares of CLLS stock, worth $3,106. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,523
Previous 330 361.52%
Holding current value
$3,106
Previous $1,000 300.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.41 - $3.09 $2,875 - $3,686
1,193 Added 361.52%
1,523 $4,000
Q4 2023

Feb 14, 2024

BUY
$0.97 - $3.55 $320 - $1,171
330 New
330 $1,000
Q4 2020

Feb 10, 2021

SELL
$15.87 - $31.64 $3,174 - $6,328
-200 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$8.21 - $21.02 $1,642 - $4,204
200 New
200 $4,000
Q3 2018

Nov 08, 2018

SELL
$25.99 - $30.6 $155,810 - $183,447
-5,995 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$27.78 - $38.53 $166,541 - $230,987
5,995 New
5,995 $170,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $92.8M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.